NORTHAMPTON, MA / ACCESSWIRE / December 20, 2022 / Quest Diagnostics:
Presbyterian Medical Services (PMS) is an FQHC that delivers integrated healthcare, education, and services to address the needs of diverse communities across the Southwest, with a specific focus on Native American populations. PMS serves more than 9,000 patients with diabetes across New Mexico. Of those patients, one-third are not adequately managing their conditions, and are therefore at risk of developing life-threatening complications.
With Q4HE's support, PMS is implementing the New Mexico Diabetes Prevention Action Plan, a comprehensive plan to provide intervention and support services for individuals living with diabetes. The Action Plan's certified diabetes educators provide counseling for tribal and other community members newly diagnosed with type 2 diabetes as well as for existing patients with uncontrolled diabetes. Follow-up services are provided in person, over the phone, and virtually to better monitor patients, address questions, and ensure medication compliance. This can include regular screenings for blood pressure, BMI, and general health to monitor HbA1c levels and make referrals for additional treatment if necessary. Additionally, PMS provides supplies including home-monitoring glucometers to enable patients to monitor and report their glucose levels more regularly.
Preventive services are crucial to help patients manage their health before conditions like diabetes develop, so PMS also provides counseling and educational resources for individuals with prediabetic symptoms.
"Adult diabetes tends to be highest among Native Americans and Hispanics across our service area, and early diagnosis, education, and continuing chronic care follow-up are key factors in reducing this health disparity. The number of uncontrolled diabetes patients has also increased in the past year partly due to reduced clinic visits and lifestyle changes caused by COVID. By partnering with Quest for Health Equity, PMS can expand access to diabetes education programs and home monitoring systems. This will create pathways for consistent health education and awareness, resulting in healthy habits and long-term positive impacts in underserved populations."
Lisa Stephens Grants and Contracts Manager, Presbyterian Medical Services
View additional multimedia and more ESG storytelling from Quest Diagnostics on 3blmedia.com.Contact Info:
Spokesperson: Quest Diagnostics
Website: http://www.questdiagnostics.com
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$163.59 |
Daily Change: | -0.30 -0.18 |
Daily Volume: | 565,007 |
Market Cap: | US$18.260B |
October 23, 2024 October 22, 2024 October 15, 2024 September 18, 2024 August 26, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB